<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382822</url>
  </required_header>
  <id_info>
    <org_study_id>Sponsor- Rigshospitalet</org_study_id>
    <nct_id>NCT02382822</nct_id>
  </id_info>
  <brief_title>Copenhagen Co-morbidity in HIV Infection Study</brief_title>
  <acronym>COCOMO</acronym>
  <official_title>Copenhagen Co-morbidity in HIV Infection Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite efficient antiretroviral treatment for HIV infection, decrease in life expectancy&#xD;
      remains. Excess mortality is mainly due to non-AIDS co-morbidity including cardiovascular,&#xD;
      pulmonary, and liver related diseases. Both HIV-unrelated and HIV-related risk factors&#xD;
      probably contribute to this pattern. At present, most evidence regarding co-morbidity in HIV&#xD;
      infection rely on cross-study comparisons of HIV-infected persons with published population&#xD;
      rates and few prospective studies in U.S. cohorts. Using well characterized participants from&#xD;
      the Copenhagen General Population Study (CGPS) as controls, we aim to include &gt;1500&#xD;
      HIV-infected persons in the COCOMO study to determine if co-morbidity is more prevalent or&#xD;
      develops at a higher rate in HIV-infected persons. The study will asses 1) cardiovascular, 2)&#xD;
      pulmonary and 3) liver-related co-morbidity using uniformly collected data in the two&#xD;
      cohorts. The investigators aim to study the relative impact of HIV-unrelated and HIV-related&#xD;
      factors on development of co-morbidity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hypothesis:&#xD;
&#xD;
      Cardiovascular disease:&#xD;
&#xD;
      - HIV infection is independently associated with higher prevalence of coronary&#xD;
      atherosclerosis (assessed by CT angiography)&#xD;
&#xD;
      Obstructive pulmonary disease:&#xD;
&#xD;
      - HIV infection is independently associated with higher prevalence of COPD, and independently&#xD;
      associated with loss of lung function&#xD;
&#xD;
      Liver disease:&#xD;
&#xD;
      - HIV infection is independently associated with liver steatosis, steatohepatitis and liver&#xD;
      fibrosis&#xD;
&#xD;
      Lipid and fat metabolism:&#xD;
&#xD;
      - HIV infection is independently associated with alterations in adipose fat tissue and&#xD;
      dyslipidemia&#xD;
&#xD;
      Secondary hypothesis:&#xD;
&#xD;
      Cardiovascular disease:&#xD;
&#xD;
        -  Viral load and CD4 are independently associated with coronary atherosclerosis (assessed&#xD;
           by CT angiography) in HIV-infected individuals.&#xD;
&#xD;
        -  Levels of inflammatory markers can predict coronary atherosclerosis in HIV-infected&#xD;
           individuals.&#xD;
&#xD;
        -  Microbial translocation and metabolism are associated with coronary atherosclerosis in&#xD;
           HIV-infected individuals.&#xD;
&#xD;
        -  Endothelial dysfunction (assessed by arterial elastography) can predict coronary&#xD;
           atherosclerosis in HIV-infected individuals&#xD;
&#xD;
      Obstructive pulmonary disease:&#xD;
&#xD;
        -  Viral load and CD4 is independently associated with emphysema&#xD;
&#xD;
        -  HIV is independently associated with pulmonary hypertension (assessed by CT&#xD;
           angiography), and obstructive lung disease is independently associated with airway&#xD;
           obstruction&#xD;
&#xD;
        -  PCP colonization in HIV infected patients is independently associated with obstructive&#xD;
           lung disease, emphysema and loss of lung function.&#xD;
&#xD;
        -  Inflammatory markers in HIV infected patients are associated with obstructive lung&#xD;
           disease and loss of lung function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary atherosclerosis</measure>
    <time_frame>Baseline cross-sectional data and after 2 years follow-up</time_frame>
    <description>Prevalence of coronary atherosclerosis; electrocardiographic abnormalities and peripheral artery disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Obstructive pulmonary disease</measure>
    <time_frame>Baseline cross-sectional data and after 2 years follow-up</time_frame>
    <description>Emphysema, airflow limitation,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver disease</measure>
    <time_frame>Baseline cross-sectional data and after 2 years follow-up</time_frame>
    <description>Prevalence of hepatic steatosis, steatohepatitis and liver fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid and fat metabolism</measure>
    <time_frame>Baseline cross-sectional data and after 2 years follow-up</time_frame>
    <description>Visceral adipose tissue, dyslipidemia, gut microbiota</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation and clonal hematopoiesis</measure>
    <time_frame>Baseline cross-sectional data and after 2 years follow-up</time_frame>
    <description>Cytokines (e.g. IL-6, TNF-alfa), cell subsets (e.g. Tregs, Th17)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emphysema, P. jirovecii colonization</measure>
    <time_frame>Baseline data(cross-sectional data)</time_frame>
    <description>Secondary pulmonary outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline data (cross-sectional data)</time_frame>
    <description>Major Depression Inventory Score, kynurenin/tryptophan ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism</measure>
    <time_frame>Baseline data(cross-sectional data) assessed after two years</time_frame>
    <description>Bone mineral density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological abnormalities</measure>
    <time_frame>Baseline data(cross-sectional data)</time_frame>
    <description>Anemia, trombocytopenia, leukopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Baseline data(cross-sectional data)</time_frame>
    <description>Kidney function</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>HIV</condition>
  <condition>COPD</condition>
  <condition>CVD</condition>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>HIV infected</arm_group_label>
    <description>Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV uninfected</arm_group_label>
    <description>Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention.</intervention_name>
    <arm_group_label>HIV infected</arm_group_label>
    <arm_group_label>HIV uninfected</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Routine biochemistry, whole blood, plasma, peripheral blood mononuclear cells (PBMCs), DNA&#xD;
      and RNA from buffy coat, plasma, and red blood cells (RBC).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  patients that are unable to understand information material&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Computed tomography(CT):&#xD;
&#xD;
          -  contraindications to CT and contrast (i.e. pregnancy, renal impairment, allergy to&#xD;
             contrast media, allergy or contraindication to beta blocking agent, body weight more&#xD;
             than 120kg, evidence of ongoing myocardial ischemia, heart rhythm precluding EKG&#xD;
             gating)&#xD;
&#xD;
        Spirometry:&#xD;
&#xD;
          -  relative contraindications to spirometry (i.e. chest, abdominal or eye surgery within&#xD;
             the 3 months before baseline spirometry, and known retinal detachment)&#xD;
&#xD;
          -  allergy or contraindications to salbutamol (i.e. &gt;110 bpm, or a known uncontrolled&#xD;
             cardiac condition (i.e. unstable coronary artery disease, decompensated heart failure)&#xD;
&#xD;
          -  a respiratory illness with at least two symptoms of breathlessness, cough, wheezing,&#xD;
             or increase in sputum production within 6 weeks.&#xD;
&#xD;
        MRI:&#xD;
&#xD;
          -  Implants (e.g. pacemaker, coclea implants, insulin pumps)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Liver Biopsy:&#xD;
&#xD;
          -  Risk of bleeding&#xD;
&#xD;
          -  Infection in puncture site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Ronit, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ditte M Kirkegaard-Klitbo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Gelpi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas D Knudsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebekka F Thudium, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malene Hove-Skovsgaard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Susanne Dam Nielsen, MD, DMSc</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

